University of California

Oregon Health & Science University

The United States Government As Represented by the Department of Veterans Affairs

Other

Thomas S Scanlan

John D Baxter

Andrew Placzek

James Matthew Meinig

Tapasree Banerji

David K Grandy

James R Bunzow

Matthew E Hart

Skylar J Ferrara

Daniel M Schwartz

Nilesh Dinbandhu Shah

Michele D Jumper

Tania Banerji

James J Apriletti

Sky Ferrara

Brian L West

Peter J Kushner

Robert J Fletterick

Andrew K Shiau

Richard L Wagner

Jordan Devereaux

Dennis Bourdette

Gail Marracci

Martin J Kelly

Jian Qiu

Grazia Chiellini

Stephen C Miller

Oline K Ronnekleiv

Hikari Ai Yoshihara

Sandra Tobias

Meredith Hartley

Marco Righi

Motonori Miyakawa

Edwin Saavedra Tan

Katherine L Suchland

Priya Chaudhary

Timothy J Mitchison

Paul Webb

Toru Iijima

Ralff C Ribeiro

Dmitry V Kadnikov

Robert J Fetterick

Sabine Borngraeber

Skylar Ferarra

Provided herein are novel amide prodrug forms of pharmaceutically active agents useful for central nervous system disorders.

Amide prodrugs of small molecule nuclear receptor modulators

Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.

Derivatives of sobetirome

Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.

Sobetirome in the treatment of myelination diseases

Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.

Amide compounds, pharmaceutical compositions thereof, and methods of using the same

Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.

Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.

Development of new selective estrogen receptor modulators

Selective estrogen receptor modulator compositions and methods for treatment of disease

The invention provides non-steroidal ligands for the glucocorticoid receptor, methods for making non-steroidal ligands of the glucocorticoid receptor, compositions of non-steroidal ligands of the glucocorticoid receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the glucocorticoid receptor for treating or preventing diseases (e.g., obesity, diabetes, depression, neurodegeneration or an inflammatory disease) associated with glucocorticoid binding to the glucocorticoid receptor.

Non-steroidal ligands for the glucocorticoid receptor, and compositions thereof

The invention provides non-steroidal ligands for the androgen receptor, methods for making non-steroidal ligands of the androgen receptor, compositions of non-steroidal ligands of the androgen receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the androgen receptor for treating or preventing diseases (e.g., prostate cancer) associated with androgen binding to the androgen receptor.

Non-steroidal antiandrogens

Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof

Growing community of inventors

San Francisco, CA, United States of America

Thomas S Scanlan